Development of a Plasma/Lung Population Pharmacokinetic Model for GSK1322322

被引：0
|
作者：
Zhu, John [1 ]
Rodvold, Keith [2 ]
Dumont, Etienne [3 ]
Tenero, David [1 ]
机构：
[1] GlaxoSmithKline, King Of Prussia, PA USA
[2] Univ Illinois, Chicago, IL USA
[3] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-031
引用
收藏
页码：S84 / S84
页数：1
相关论文
共 50 条
  • [1] Development of a Plasma/Dermis Population Pharmacokinetic Model for GSK1940029
    Zhu, John
    Wilde, Thomas
    Brigandi, Richard
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S99 - S99
  • [2] Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322
    O'Dwyer, Karen
    Hackel, Meredith
    Hightower, Sarah
    Hoban, Daryl
    Bouchillon, Samuel
    Qin, Donghui
    Aubart, Kelly
    Zalacain, Magdalena
    Butler, Deborah
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) : 2333 - 2342
  • [3] The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
    Naderer, Odin
    Jones, Lori S.
    Zhu, John
    Coffin, Mark D.
    Kurtinecz, Milena
    Dumont, Etienne
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 49 - 55
  • [4] In Vitro and Intracellular Activities of Peptide Deformylase Inhibitor GSK1322322 against Legionella pneumophila Isolates
    Dubois, Jacques
    Dubois, Maitee
    Martel, Jean-Francois
    Aubart, Kelly
    Butler, Deborah
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 707 - 710
  • [5] Safety, Tolerability, and Pharmacokinetics of Oral and Intravenous Administration of GSK1322322, a Peptide Deformylase Inhibitor
    Naderer, Odin J.
    Jones, Lori S.
    Zhu, John
    Kurtinecz, Milena
    Dumont, Etienne
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (11): : 1168 - 1176
  • [6] Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage
    Naderer, Odin J.
    Rodvold, Keith A.
    Jones, Lori S.
    Zhu, John Z.
    Bowen, Chester L.
    Chen, Liangfu
    Dumont, Etienne
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 419 - 423
  • [7] Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections
    Corey, Ralph
    Naderer, Odin J.
    O'Riordan, William D.
    Dumont, Etienne
    Jones, Lori S.
    Kurtinecz, Milena
    Zhu, John Z.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6518 - 6527
  • [8] Microbiome Changes in Healthy Volunteers Treated with GSK1322322, a Novel Antibiotic Targeting Bacterial Peptide Deformylase
    Arat, Seda
    Spivak, Aaron
    Van Horn, Stephanie
    Thomas, Elizabeth
    Traini, Christopher
    Sathe, Ganesh
    Livi, George P.
    Ingraham, Karen
    Jones, Lori
    Aubart, Kelly
    Holmes, David J.
    Naderer, Odin
    Brown, James R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1182 - 1192
  • [9] Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor
    Ross, James E.
    Scangarella-Oman, Nicole E.
    Miller, Linda A.
    Sader, Helio S.
    Jones, Ronald N.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (11) : 3928 - 3930
  • [10] Single-Dose Safety, Tolerability, and Pharmacokinetics of the Antibiotic GSK1322322, a Novel Peptide Deformylase Inhibitor
    Naderer, Odin J.
    Dumont, Etienne
    Zhu, John
    Kurtinecz, Milena
    Jones, Lori S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) : 2005 - 2009
12345